4.8 Article

Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies

Journal

LANCET
Volume 377, Issue 9771, Pages 1085-1095

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(11)60105-0

Keywords

-

Funding

  1. National Heart, Lung and Blood Institute
  2. diaDexus
  3. Merck
  4. Department of Health
  5. British Heart Foundation [RG/08/014]
  6. National Institutes of Health
  7. National Cancer Institute
  8. AstraZeneca
  9. Novartis
  10. Bristol-Myers Squibb
  11. Schering-Plough
  12. Bayer
  13. Solvay
  14. BUPA Foundation
  15. Denka
  16. European Union
  17. Evelyn Trust
  18. Fogarty International Centre
  19. GlaxoSmithKline
  20. Pfizer
  21. Roche
  22. UK Biobank
  23. UK Medical Research Council
  24. Wellcome Trust
  25. Allergan
  26. National Institute of Neurological Disorders and Stroke
  27. MRC [MC_U137686857, MC_U105260792, G0600705, G0701619, G0701113] Funding Source: UKRI
  28. British Heart Foundation [RG/08/014/24067, PG/09/002/26056] Funding Source: researchfish
  29. Medical Research Council [G0701113, G0701619, G0401527, G1000143, MC_U137686857, G0600705, MC_U105260792] Funding Source: researchfish

Ask authors/readers for more resources

Background Guidelines differ about the value of assessment of adiposity measures for cardiovascular disease risk prediction when information is available for other risk factors. We studied the separate and combined associations of body-mass index (BMI), waist circumference, and waist-to-hip ratio with risk of first-onset cardiovascular disease. Methods We used individual records from 58 cohorts to calculate hazard ratios (HRs) per 1 SD higher baseline values (4.56 kg/m(2) higher BMI, 12.6 cm higher waist circumference, and 0 083 higher waist-to-hip ratio) and measures of risk discrimination and reclassification. Serial adiposity assessments were used to calculate regression dilution ratios. Results Individual records were available for 221 934 people in 17 countries (14 297 incident cardiovascular disease outcomes; 1.87 million person-years at risk). Serial adiposity assessments were made in up to 63 821 people (mean interval 5.7 years [SD 3.9]). In people with BMI of 20 kg/m2 or higher, HRs for cardiovascular disease were 1.23 (95% CI 1.17-1.29) with BMI, 1.27 (1.20-1.33) with waist circumference, and 1.25 (1.19-1.31) with waist-to-hip ratio, after adjustment for age, sex, and smoking status. After further adjustment for baseline systolic blood pressure, history of diabetes, and total and HDL cholesterol, corresponding HRs were 1 07 (1.03-1.11) with BMI, 1.10 (1.05-1.14) with waist circumference, and 1.12 (1.08-1.15) with waist-to-hip ratio. Addition of information on BMI, waist circumference, or waist-to-hip ratio to a cardiovascular disease risk prediction model containing conventional risk factors did not importantly improve risk discrimination (C-index changes of -0.0001, -0.0001, and 0.0008, respectively), nor classification of participants to categories of predicted 10-year risk (net reclassification improvement -0.19%, -0.05%, and -0.05%, respectively). Findings were similar when adiposity measures were considered in combination. Reproducibility was greater for BMI (regression dilution ratio 0.95, 95% CI 0.93-0.97) than for waist circumference (0.86, 0.83-0.89) or waist-to-hip ratio (0.63, 0.57-0.70). Interpretation BMI, waist circumference, and waist-to-hip ratio, whether assessed singly or in combination, do not importantly improve cardiovascular disease risk prediction in people in developed countries when additional information is available for systolic blood pressure, history of diabetes, and lipids.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available